secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003949
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte acquires C2i Genomics for $70M in stock; reports preliminary 2023 revenue up 21%
--------------------------------------------------------------------------------

- Q4 2023 revenue $95-96M (+18-20% YoY); full-year revenue $358-359M (+21%).
- Total test volume ~34,000 in Q4 (+21%), ~127,000 full-year (+24%).
- 2024 revenue guidance 10-12% growth ($394-402M); cash >$215M at year-end.
- Acquires C2i Genomics for $70M in Veracyte shares at close plus up to $25M milestone; expected close Q1 2024.
- First MRD test in muscle-invasive bladder cancer, leveraging urology commercial channel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer